Abstract
Cetuximab plus chemotherapy has been approved as first-line (1L) treatment for mCRC. However, real-world evidence of cetuximab for mCRC in Asian population remains inadequate. The objective of this large-scale, multicenter retrospective study was to report real-world treatment patterns and clinical outcomes of Taiwanese patients with RAS WT mCRC received 1L cetuximab-based chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
